今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001357550-20-000031 Act: 34 Size: 108 KB 网页链接
$Trident(TDAC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001062993-20-000752 Act: 34 Size: 34 KB 网页链接
$Trident(TDAC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000912282-20-000030 Act: 34 Size: 87 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 1.01, 5.03, 5.07, and 9.01 Accession Number: 0001213900-19-024948 Act: 34 Size: 68 KB 网页链接
$Trident(TDAC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-19-023889 Act: 34 Size: 1 MB 网页链接
$Trident(TDAC)$ NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB Accession Number: 0001213900-19-023530 Act: 34 Size: 38 KB 网页链接
$Trident(TDAC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-19-023055 Act: 34 Size: 85 KB 网页链接
$Trident(TDAC)$ DEF 14A - Other definitive proxy statements Filed: 2019-11-06 AccNo: 0001213900-19-022187 Size: 220 KB 网页链接
$Trident(TDAC)$ DEFR14A - Revised definitive proxy soliciting materials Filed: 2019-11-06 AccNo: 0001213900-19-022246 Size: 220 KB 网页链接
$Trident(TDAC)$ PRE 14A - Other preliminary proxy statements Filed: 2019-10-21 AccNo: 0001213900-19-020643 Size: 223 KB 网页链接